Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial

Moini, Ashraf; Kanani, Mahia; Kashani, Ladan; Hosseini, Reihaneh; Hosseini, Ladan

doi:10.1007/s12020-014-0426-4

Cited by 21 publications

(57 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In terms of applicability, we found that the valid and important studies may not be highly applicable in our setting. The reason being is that although the age group and clinical characteristics were similar to that of our setting (that is, women of reproductive age with PCOS-related obesity), we found several issues regarding different ethnicity which potentially causes different dietary habit, the side effects reported by Moini et al [15] , and drug's feasibility. Orlistat is readily available in Indonesia yet it is rather expensive.…”

Section: Critical Appraisalmentioning

confidence: 67%

“…However, they used small sample size and did not use blinding method, making the study susceptible to observer bias. The study by Moini et al [15] was also considered strong, had a proper recruitment process and randomization for the same reasons as above. In addition, they also utilized double blinding method to prevent observer bias.…”

Section: Discussionmentioning

confidence: 99%

“…From the search selection and filtration above, two eligible RCT articles were selected to be reviewed: Kumar Both selected studies were critically appraised for their validity, importance, and applicability. Both studies from Kumar and Arora [14] and Moini et al [15] failed to mention allocation method. Nevertheless, the two studies fulfilled 4 out of 6 validity criteria, thus regarded as valid.…”

Section: Critical Appraisalmentioning

confidence: 99%

“…There were statistically significant reduction in weight, BMI, and WHR between intervention and control groups (Table 3). Moini et al [15] also reported about adverse events experienced by 50% of the patients in the intervention group including oily spotting, oily stools, and headache. In contrast to previous study, this study might be more similar to Indonesia in terms of dietary habit as it was conducted in Iran.…”

Section: The Evidencementioning

confidence: 99%

“…Moini et al [15] conducted a randomized, double-blind, controlled trial, which involved 100 patients that were randomized into two groups using randomization table method. Participants recruited were female aging between 19-38 years old with PCOS and BMI >25 kg/m 2 .…”

Section: The Evidencementioning

confidence: 99%

See 4 more Smart Citations

The Effect of Orlistat as an Adjuvant to Lifestyle Modification on Weight Loss in Polycystic Ovary Syndrome Patients:An Evidence-Based Case Report

André¹,

Aristyo²,

Zhafira³

et al. 2017

IOSRPHR

View full text Add to dashboard Cite

: Polycystic ovary syndrome (PCOS) occurs in 1 of 10 women of reproductive age. This syndrome is highly associated with obesity. Therefore, many of the patients face weight loss challenges. Given that many patients find it rather difficult to change their lifestyle, medicamentous intervention poses an option. Orlistat is an inhibitor of carboxyl ester lipase which inhibits the hydrolysis of dietary triglycerides that decreases the absorption of fatty acids and monoglyceride. The purpose of this study is to determine whether administration of orlistat can improve diet and exercise-induced body weight reduction in PCOS patients with obesity. Literature searching was done in 3 databases: PubMed, Cochrane Library, and Embase which yielded 141 articles. Findings were narrowed down using duplicate removal, inclusion and exclusion criteria into two relevant articles of randomized controlled trials. One randomized clinical trial showed a greater percentage in weight loss in PCOS patients BMI>23 kg/m2 administered with orlistat and lifestyle modification in comparison to lifestyle modification alone (7.81% (6.51-9.11%) vs 4.7% (4.19-5.21%) ; p<0.001). Similar body weight reduction was also found by another randomized clinical trial in PCOS patients BMI>25 kg/m2 with orlistat treatment (from 81.5 kg (80.3-82.7) to 76.2 kg (74.92-77.48) vs from 80.91 kg (79.65-82.17) to 79.15 kg (77.8-80.5) ; p<0.01). It was concluded that a considerable reduction of weight in obese and overweight PCOS patients was found when given orlistat with exercise and dietary interventions compared to exercise and dietary interventions alone.

show abstract

Section: Critical Appraisalmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%